Apricot Capital

← Back to your selection

All recorded activity

Rounds participated in: 4
Confirmed lead rounds: —
New companies: 4
Funding in participating rounds: $192.7M

By stage

Series A3

Seed1

By primary sector

Biotech4

By country

China4

Rounds

4 in all activity

Apr 29

Vivacta Biotechnology

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+

Role not disclosed

Apr 10

Vivatides Therapeutics

Develops extrahepatic RNA-targeting therapeutics

$54MSeries A

Role not disclosed

Mar 18

Excalipoint Therapeutics

Develops next-generation T-cell engager therapies for cancer and autoimmune diseases

$27.7MSeed+

Role not disclosed

Jan 12

Vibrant Therapeutics

Develops intelligent, logic-gated therapeutics for solid tumors

$61MSeries A

Role not disclosed

← Back to your selection

All recorded activity

Rounds participated in: 4
Confirmed lead rounds: —
New companies: 4
Funding in participating rounds: $192.7M

By stage

Series A3

Seed1

By primary sector

Biotech4

By country

China4

Rounds

4 in all activity

Apr 29

Vivacta Biotechnology

Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases

$50MSeries A+

Role not disclosed

Apr 10

Vivatides Therapeutics

Develops extrahepatic RNA-targeting therapeutics

$54MSeries A

Role not disclosed

Mar 18

Excalipoint Therapeutics

Develops next-generation T-cell engager therapies for cancer and autoimmune diseases

$27.7MSeed+

Role not disclosed

Jan 12

Vibrant Therapeutics

Develops intelligent, logic-gated therapeutics for solid tumors

$61MSeries A

Role not disclosed